Cellistic develops processes to differentiate hiPSC into immune cells using bioreactors and proprietary know-how for customers. The Cell Therapy Innovation (CTI) group (15 direct reports), within Cellistic, focuses on identifying pathways involved in differentiation of Stem cells into progenitors and functional differentiated cells. The CTI also performs scale up of differentiation processes into bioreactors with the objective of transferring the technologies to Cellistic's GMP manufacturing unit.Eventually, CTI is the expert group that merge Cellistic's technologies with the client technologies and ensure robust, efficient manufacturing of cell therapies.

Expert in cell therapies development. - Mentoring and coaching of Scientists on autologous/allogeneic CAR T R&D projects for heme and for Solid- Managing personal R&D projects from the original concept to completion- Identification and implementation of novel technologies- Participation to R&D department objectives definitionExpertises:Managerial : Project management, team technical lead, CRO/CMO (contact, contract and follow up), Publication, Patents (support application)Technical : Cell culture, Flow cytometry, qPCR, ELISA, Incucyte, multiplex assay, SC secretome technologies, Seahorse, co-culture assay, pre-clinical model study design, RNA seq, cloning, shRNA, CRISPR…

Managing Autologous/allogeneic CAR T related R&D projects from the original concept to completion. Creative, provide R&D department with innovative ideas.Expertises: Project management, CRO management, Publication, Patents, Cell culture, Flow cytometry, qPCR, ELISA, Incucyte, multiplex assay, SC secretome technologies, co-culture assay, pre-clinical model study design, RNA seq, cloning, shRNA, CRISPR.

Stem cell platform: Planning and achievement of experiments. Data analysis, report writing under management supervision. Expertises: MSC’s purification (BM aspirate), cardiomyocyte differentiation, QC check, testing of new media, cytokine, and PL to support process.CAR T platform:Planning and achievement of experiments. Data analysis, report writing under management supervision. Tech transfer: Expert in Cell therapy technology, Itransfer of the CYAD-01 technology from R&D to the manufacturing facilities.Process development: CYAD-01 technology was jeopardized by a phenomenon called fratricide. Responsible for testing of multiple strategies to overcome fratricide.

Doctoral research- Study of the influence of Cancer/testis antigens (MAGE-A family) on p53 dependent apoptosis. - Study of the apoptosis induced by Resveratrol.Teaching activities-Supervisor of three undergraduate students for their master thesis.-LBIO1181: “Project” (45h practical work). Management of 6 first year students: creation of a poster, development of communication skills and critical analysis. (2011 to 2013)-LBIO1111: "Animal biology". Management of practical work: dissection.

Research on the impact of bacterial peptides on gut inflammation.Publication : Dalmasso et al. 2010, PepT1 mediates transport of the proinflammatory bacterial tripeptide L-Ala-{gamma}-D-Glu-meso-DAP in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol , Sep;299(3):G687-96.